Spots Global Cancer Trial Database for lung, carcinoma
Every month we try and update this database with for lung, carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer | NCT02139579 | Lung, Carcinoma | Bevacizumab | 18 Years - 75 Years | Sun Yat-sen University | |
Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | NCT03151161 | Lung, Carcinoma | Icotinib,Pemetr... Icotinib | 18 Years - 75 Years | Sun Yat-sen University | |
Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | NCT02066038 | Lung, Carcinoma | Erlotinib | 18 Years - 75 Years | Sun Yat-sen University | |
Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer | NCT02139579 | Lung, Carcinoma | Bevacizumab | 18 Years - 75 Years | Sun Yat-sen University | |
Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | NCT02066038 | Lung, Carcinoma | Erlotinib | 18 Years - 75 Years | Sun Yat-sen University |